



Press Release

ProStrakan Group plc

ProStrakan announces an exclusive licence and collaboration agreement with Amgen to develop and commercialise compounds for renal disease

Galashiels, Scotland, 13 July 2006 - ProStrakan Group plc (LSE: PSK), the European specialty pharmaceutical company, announces today an exclusive licence and collaboration agreement with Amgen, the world's largest biotechnology company, to research, develop and commercialise certain of ProStrakan's preclinical compounds for renal disease.

Under the terms of the agreement, ProStrakan has granted Amgen an exclusive worldwide licence for the development and commercialisation of its compounds in exchange for an initial upfront payment of \$7 million and research collaboration funding of \$1.1 million for the first year with the possibility of extending it thereafter. Further payments will be made at undisclosed milestones. ProStrakan will be eligible for royalties on net sales of licensed products on a worldwide basis. In addition to the initial upfront payment, research collaboration funding and future royalties ProStrakan will receive milestone payments upon successful completion of certain pre-clinical, clinical, regulatory and commercial events, which could ultimately total in excess of \$150 million.

Commenting on the deal, **Dr Wilson Totten, CEO of ProStrakan**, said "We are delighted to enter into this collaboration with Amgen whose expertise as a leading biotech company will help drive this project forward towards commercialisation. This agreement recognises the world class research carried out by our discovery unit and helps take us a step closer to realising our long term goal to build a cash-generative, sustainable pharmaceutical company."

For more information, please contact:

ProStrakan	+44 (0)1896 664000
Wilson Totten, CEO	
Adrian Gardner, CFO	
Jo Bowler	+44 (0)1896 664104
Financial Dynamics	+44 (0)20 7831 3113
Sarah MacLeod	

Notes to Editors

ProStrakan

ProStrakan Group plc is a rapidly growing international specialty pharmaceutical company engaged in the research, development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets. The Company's therapeutic focus is on bone diseases, women's health and issues relating to the ageing male. Headquartered in Scotland, the Company's R&D facilities are situated in Romainville, near Paris, and in Galashiels in Scotland. EU-wide sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries based in the UK, France, Germany and Spain.

ProStrakan was listed on the London Stock Exchange in June 2005.

On 23 March 2006, the Company announced its Preliminary Results for 2005: revenues up 47% to £31.6 million; gross profit up 69% to £16.7 million.

www.prostrakan.com